Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
10.89
+0.02 (0.18%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe.
The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown.
It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolus, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Feb 8, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 273 |
| CEO | David Moatazedi |
Contact Details
Address: 520 Newport Center Drive, Suite 1200 Newport Beach, California 92660 United States | |
| Phone | 949 284 4555 |
| Website | evolus.com |
Stock Details
| Ticker Symbol | EOLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001570562 |
| CUSIP Number | 30052C107 |
| ISIN Number | US30052C1071 |
| Employer ID | 46-1385614 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Moatazedi | President, Chief Executive Officer and Director |
| Sandra Beaver | Chief Financial Officer |
| Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of Research and Development |
| Nareg Sagherian | Head of Global Investor Relations and Corporate Communications |
| Jeffrey J. Plumer | General Counsel |
| Kurt Knab | Vice President of Sales |
| Tomoko Yamagishi-Dressler | Chief Marketing Officer |
| Jessica Novak | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Jul 31, 2024 | 10-Q | Quarterly Report |
| Jul 31, 2024 | 8-K | Current Report |
| Jul 1, 2024 | 8-K | Current Report |